Werner syndrome | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

28,931 results for “Werner syndrome”

Trials

View all 25646 →

Not yet recruiting

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

5 participants · First posted May 6, 2023

Phase I Study of Progerinin in Healthy Volunteers

64 participants · First posted Aug 14, 2020

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

2 participants · First posted Nov 24, 2008

Drugs

View all 256 →

Werner syndrome ATP dependent helicase inhibitor (cancer)

Leigh syndrome therapeutic(Leigh syndrome)

Werner inhibitor (MSI-high cancers/sensitive cancers)

Organizations

View all 38 →

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

News

View all 2991 →

First Clinical Trial Shows Nicotinamide Riboside Improves Multiple Health Outcomes in Werner Syndrome Patients

Nimbus Therapeutics Completes Dose Escalation for Novel WRN Inhibitor NDI-219216 in MSI-H Tumors

WRN Inhibitors Enter Clinical Development Phase as Precision Oncology Market Expands

Page 1 of 2894